Articles
Buy HII: Navy Rebuild + Execution Should Lift Huntington Ingalls Into a Premium Spot
Actionable long: enter on strength or small pullback — targets, stops, and the reasons to own America's largest independent shipbuilder.
Huntington Ingalls (HII) is a cash-generative, high-barrier-to-entry shipbuilder benefiting from renewed U.S. Navy procurement and recent contract/new...
BridgeBio: Commercial Momentum + Clinical Wins Make This a Tactical Long
Recent clinical readouts and initial commercial traction justify a constructive, risk-aware entry into BBIO
BridgeBio (BBIO) has moved from clinical-stage story to commercial execution in 2025. Positive Phase 3 / OLE data for acoramidis, a UK approval, and a...
Williams-Sonoma: Solid Comps, Margin Momentum, and a Tactical Long Trade into Tariff Noise
Healthy low-single-digit comps, improving gross margins in recent quarters, and steady cash generation justify a tactical long with defined risk.
Williams-Sonoma reported steady comps across the last few quarters with improving margin mechanics in the most recent print, strong operating cash flo...
Why Nvidia Is Not a Bubble: Profits, Margins and an Actionable Trade
Strong cash flow, industry-leading margins and low leverage make NVDA a buyable growth story — with defined risk controls.
Nvidia's latest quarter (ended 10/26/2025) delivered exceptional margins, large net income and cash generation that justify a premium multiple. This i...
Nebius (NEBI): An Undercovered Small-Cap with Asymmetric Upside - A Tactical Long
Play the information vacuum - disciplined entry, tight stop, staged targets.
NEBI is an undercovered ticker that looks like a classic asymmetric trade: limited public disclosure, low market attention, and a path for re-rating i...
Arq (ADES): Rebrand and Contracts Clear the Fog — Visibility Improved, Risks Intact
Operational inflection, stronger balance sheet — tradeable long with tight risk controls for patient, capital-light traders.
Arq (formerly Advanced Emissions Solutions) has taken concrete steps toward clearer revenue visibility after a 2024 rebrand and recent plant expansion...
ExxonMobil: Cash, Scale and a Dividend — The Market is Missing the Durable Cash Engine
Strong cash flow, disciplined capital allocation and a material dividend make XOM a high-conviction buy at current levels.
Exxon Mobil (XOM) is generating large, reliable cash flow while preserving a conservative balance sheet and returning capital aggressively. Recent qua...
Intel’s Most Unusual Bull Case: Real Operating Repair or Accounting Mirage?
A contrarian, actionable long with entry, stops and layered targets based on Q3/FY2025 results and a run-rate valuation
Intel’s 11/06/2025 quarter shocked the market: a $4.27B GAAP net income and $0.90 diluted EPS on $13.65B revenue while operating income was only $68...
ExxonMobil Is Underpriced: Buy a High-Cash, Dividend-Rich Energy Giant
Strong cash generation, rising payout and disciplined capital allocation make XOM a tactical long—entry, stops and targets included.
ExxonMobil (XOM) is generating large operating cash flow, returning capital aggressively through dividends and buybacks, and sitting on a fortress bal...
Copper Tightening, Cash Flows Growing: Why Southern Copper (SCCO) Is a Compelling Long
A position trade that leans on copper deficits, heavy free cash flow, steady dividends and a clean balance sheet — entry, stops and targets included.
Southern Copper is one of the lowest-cost, integrated copper producers with strong recent cash flow, an increasing dividend cadence and exposure to a ...
Semiconductor Cyclical Reset Complete? PSI Looks Like a Tactical Long After the Drawdown
Invesco Semiconductors ETF (PSI) — valuation has largely reset; sector-level fundamentals and flows are aligning for a follow-through rally.
PSI traded through a brutal intra-year drawdown and now sits near multi-month highs (~$80.80). With AI-driven chip demand, an improving memory cycle a...
Take Profits on Teva — Downgrade and a Short‑on‑Strength Trade Plan
Fundamentals improved, but valuation, leverage and earnings volatility argue it's time to cash out or short a bounce.
Teva's recent operational rebound (Q3 2025 revenues $4.48B, net income $433M) has been priced aggressively. Balance‑sheet leverage, persistent non�...